Editing PHKG Business Opportunities (section)

== 2. B2B Preventive Health — Employee Health Programs ==

'''Concept:''' Employer pays for employee health screening, data stored in a PHKG, tracked over years. Employees get personalized health insights. Employer gets healthier workforce and retention benefits.

'''Note:''' The wiki's earlier version claimed "typical ROI: €2-5 saved per €1 spent on wellness." This is the observational/industry-marketing figure. The rigorous causal evidence does not support it (see ROI evidence below).

=== How It Works ===

# Employer contracts Stamen for employee health program
# Employees get periodic health screenings (blood tests, body scans, questionnaires) — partner with Neko Health, Nightingale Health, or local providers
# Screening data is curated into individual PHKGs
# AI analyzes trends over time: cholesterol trajectory, blood pressure trends, metabolic markers
# Employee gets personalized health dashboard with recommendations
# Employer gets anonymized aggregate workforce health reports

=== Market Context ===

'''Corporate wellness market:''' Estimated $61B globally (2024), growing 7-8% annually.

'''Existing players:'''
* '''Neko Health''' (Sweden, $2.55B) — full-body scanning, launched B2C but trajectory toward employer contracts. If Neko builds their own B2B data platform, the "PHKG backend" partnership is competing with their in-house roadmap.
* '''Nightingale Health''' (Finland, public) — blood test biomarker platform. Already sells to employers. Less a partner, more a competitor to the data-tracking layer.
* '''Wellhub/Gympass''' (Brazil/US) — fitness/wellness platform. Not health data.
* '''Virgin Pulse / Personify Health''' — enterprise wellness. Generic, not data-centric.
* '''Norwegian BHT providers:''' Stamina Helse, Avonova, Falck Helse, Synergi Helse. Regulated occupational health services sector under Arbeidsmiljøloven. Already do periodic employee health screenings, sell to employers, have multi-year contracts. They collect screening data but don't structure it well. The realistic play in Norway is partnering with or selling into BHT providers, not bypassing them. (Primary sources to confirm: Arbeidstilsynet, Helsedirektoratet.)
* '''Insurance-bundled:''' Storebrand Helse, If, Tryg, Fremtind increasingly bundle preventive screening with employer health insurance. Missing from earlier wiki analysis.

=== ROI Evidence — The Honest Picture ===

'''Industry marketing:''' Surveys and observational studies report $2–6 ROI per $1 spent on wellness. The Harvard meta-analysis found medical costs fall by ~$3.27 per $1 invested. J&J case studies report similar.

'''RCT evidence:''' Consistently null or modest when selection bias is controlled for.

* A 3-year cluster-randomized trial (160 worksites, 25 treatment / 135 control) found better self-reported health behaviors in first 18-24 months but '''little evidence of reduced healthcare spending, improved objective health measures, or changed outcomes.''
* The RAND Wellness Programs Study (Fortune 100 employer, 10 years) found overall ROI of $1.50/dollar. Disease management returned $3.80, but '''lifestyle/screening returned just $0.50 per dollar — i.e., lost money.''' Lifestyle/screening is what Stamen would offer.
* A quasi-experimental small-employer study estimated ROI of $0.585/participant with 95% CI: -$35.095 to $14.103 — wide confidence intervals straddling zero.
* Reif (2020) review: workplace wellness programs unlikely to significantly improve employee health or reduce medical use in the short term.

'''The discrepancy:''' Observational results ($2–6 ROI) are driven by self-selection — healthier employees voluntarily participate, then their lower costs get attributed to the program. RCTs controlling for this find the effect largely disappears.

'''Defensible claim:''' "Hard ROI is contested. The realistic value proposition to employers is talent/retention/engagement, not direct medical-cost savings."

=== Revenue Potential (corrected) ===

* '''Per-employee subscription:''' €20-50/month per employee for screening + data platform
* '''Realistic participation:''' 20-40% (wiki earlier noted this but the example assumed 100%)
* '''Corrected example:''' 500 employees × 30% participation × €30/month = €4,500/month = €54,000/year per client
* '''With 10 employer clients:''' €540K ARR (not €1.8M as previously stated)
* This changes unit economics materially — margins are tight.

=== Privacy — Near-Blocking Constraint in EU ===

The wiki earlier noted "employee privacy concerns" briefly. In the EU/Norway, this is a near-blocking constraint, not a soft concern:

* Health data is GDPR Article 9 special category data — requires explicit consent or specific legal basis.
* '''Employer-employee consent is presumptively invalid under GDPR''' because of power imbalance (EDPB Opinion 2/2017). You can't get free consent from an employee for their employer-funded health program.
* Norwegian Datatilsynet has been particularly active on employer data processing.
* Even with "employee sees own data, employer sees aggregates" model, the processor (Stamen) handles Article 9 data on behalf of an employer that arguably can't lawfully be the controller.
* '''Required architecture:''' Employee-as-controller, employer-as-payer, with no employer access even to aggregates of identifiable subgroups. Harder to sell than the wiki implies.

=== Challenges ===

* '''ROI doesn't survive RCT scrutiny:''' The sell to employers is talent/retention/risk-management, not direct healthcare savings — softer, slower sale.
* '''BHT incumbents own the employer relationship:''' Going around them is hard; going through them requires partnership terms that compress margins.
* '''GDPR Article 9 + employee consent:''' Near-blocking constraint on data architecture. Employer can't be data controller for employee health data.
* '''Participation rates 20-40%:''' Unit economics ~3x worse than wiki's original example.
* '''Not a core competency:''' Different sales motion (HR director, not hospital CIO). Distracts from core EHDS play.
* '''Competitive density:''' Neko's likely B2B roadmap, Nightingale's existing employer business, BHT providers, insurer-bundled offerings all crowd the space.

=== Verdict ===

'''The verdict "distraction from core EHDS play" is correct — and the underlying business case is actually LESS attractive than the wiki's own verdict suggested.'''

The hard ROI claim doesn't survive contact with RCT literature. Norway has an entrenched BHT channel. GDPR Article 9 makes the data architecture more constrained than it appears. Participation rates mean unit economics are roughly 3x too optimistic in the original example.

Best pursued as a year 3+ partnership play: provide PHKG backend for a BHT provider or insurer, don't build the screening/sales operation. Even then, the value proposition to employers should be framed as talent/retention/engagement — not healthcare savings.